Yearbook of Intensive Care and Emergency Medicine 2009

von: Jean-Louis Vincent

Springer-Verlag, 2009

ISBN: 9783540922766 , 998 Seiten

Format: PDF, OL

Kopierschutz: Wasserzeichen

Windows PC,Mac OSX geeignet für alle DRM-fähigen eReader Apple iPad, Android Tablet PC's Online-Lesen für: Windows PC,Mac OSX,Linux

Preis: 128,39 EUR

Mehr zum Inhalt

Yearbook of Intensive Care and Emergency Medicine 2009


 

Table of Contents

5

List of Contributors

11

Common Abbreviations

28

I Genomics and Proteomics

29

Rethinking Sepsis: New Insights from Gene Expression Profiling Studies

30

Introduction

30

How to Identify and Measure Heterogeneity

30

Sources of Heterogeneity in Sepsis Patients

31

New Insights from Gene-expression Studies

32

Genomic Heterogeneity

34

Further Questions on an Existing Sepsis Model

36

Functional Mapping of Sepsis Genome to Monitor Immune Function

37

Conclusion

39

References

39

Mitochondrial Genetics and Sepsis

41

Introduction

41

Oxidative Phosphorylation and ATP Generation

41

Reactive Oxygen Species

42

Apoptosis

42

Mitochondria and Sepsis

43

Mitochondrial Genetics

43

Mitochondrial Haplogroups

44

Conclusion

47

References

47

Lung Proteomics in Intensive Care

50

Introduction

50

The Search for Biomarkers

50

Lung Proteomics

52

Applications in ALI/ARDS

58

Future Directions

59

References

62

II Inflammatory Response

64

The Host Response to Sepsis

65

Introduction

65

Epidemiology and Genetic Variability

66

Pathogen Recognition Systems

67

Coagulation and Anticoagulation

70

Immune Suppression and Apoptosis

72

HMGB1 and RAGE

72

The Cholinergic Anti-inflammatory Pathway

73

Macrophage Migration Inhibitory Factor

74

C5a and C5a Receptor

74

Conclusion

74

References

74

Endotoxin Tolerance: Mechanisms and Clinical Applicability

77

Introduction

77

Mechanisms of Endotoxin Tolerance

77

Endothelial Function and Microcirculation during LPS Tolerance

79

Clinical Applicability and Therapeutic Possibilities

81

Conclusions

82

References

82

Oxidative Stress and Endothelial Dysfunction during Sepsis

85

Introduction

85

Sources and Actions of ROS and RNS in the Endothelium during Sepsis

85

Mechanisms of Endothelial Dysfunction during Sepsis

87

Conclusion

89

References

90

Measurement of Carbon Monoxide: From Bench to Bedside

91

Introduction

91

Carbon Monoxide Measurement

91

Carbon Monoxide Concentrations in Critically Ill Patients

92

Carbon Monoxide Concentrations and Lung Diseases

96

Carbon Monoxide Concentrations and Other Diseases

103

Conclusion

103

References

103

Monitoring Immune Dysfunction in Septic Patients: Toward Tailored Immunotherapy

107

Introduction

107

Monocyte Dysfunction

108

T Lymphocyte Dysfunction

111

Conclusion

114

References

115

III Current and Future Management of Sepsis

117

Source Control in the ICU

118

Introduction

118

What is ‘Source Control’?

118

Elements of Source Control

119

Do we need to perform Source Control?

120

When to Perform Source Control?

121

The Role of the Intensivist

121

What if Source Control is Impossible or Fails?

123

Special Considerations in Critically Ill Patients

123

Conclusion

125

References

125

IgM-enriched Immunoglobulins in Sepsis

127

Introduction

127

Mechanisms of Action of IVIG in Sepsis

128

Differences between IgG- and IgM-enriched Immunoglobulins

129

Clinical Significance of IgM-enriched IVIG

130

Conclusion

133

References

134

Clarithromycin: A Promising Immunomodulator in Sepsis

136

Introduction

136

Indirect Evidence for an Immunomodulatory effect of Macrolides in Pneumonia

137

Lessons from Animal Studies

138

Conclusion

141

References

142

High-flow Hemofiltration as an Adjunctive Therapy in Sepsis

144

Introduction

144

Mechanism of Action: Hemofiltration as a New Shield against the ‘Chaos Theory’ and ‘Complex Non-linear Systems’ in Sepsis

144

Recent Animal Trials and Clinical studies Highlighting the Crucial Roles of Dosing and Timing

146

Practical Aspects for the Bedside Clinician

148

Future Directions Regarding the Use of Hemofiltration in Sepsis

149

Conclusion

150

References

151

Economic and Social Burden of Severe Sepsis

154

Introduction

154

Concepts

154

Direct Costs of Sepsis Management

156

Direct Costs of Sepsis Management in Developing Countries: A Brazilian Experience

157

Indirect Costs and Burden of Illness

158

Impact of Therapeutic Strategies on Costs

159

Conclusion

161

References

162

IV Proposed Targets for New Therapies

164

Lymphocyte Apoptosis in Sepsis and Potential Anti-apoptotic Strategies

165

Introduction

165

Mechanisms of Apoptosis

166

Pathways Involved in Apoptosis

166

Evidence in Animals

168

Evidence in Humans

170

Therapeutic Molecular Targets

171

Conclusion and Perspectives

172

References

172

The Pivotal Role of Beta-adrenoreceptors in Critical Illness Pathophysiology

175

Introduction

175

New Concepts in Adrenoreceptor Signaling Biology

175

Desensitization of Beta-adrenoreceptors

177

Catecholamine-induced Immune Dysregulation

178

Beta-adrenoreceptor-mediated Metabolic Effects of Critical Illness

180

Beta-adrenoreceptor-mediated Effects on Barrier Gut Function

181

Specific Beta-adrenoreceptor-mediated Roles in Common Critical Illness Pathophysiology

181

Limitations of Current Experimental/clinical Data

182

Conclusion

182

References

183

Non-septic Acute Lung Injury and Inflammation: Role of TLR4

186

Introduction

186

Participation of TLR4 in Ischemia-reperfusion Injury

186

Heme Activates TLR4 by Different Mechanisms than does LPS

187

Acute Lung Injury Produced by Avian Influenza Virus H5N1 or Acid Aspiration is Dependent on Activation of TLR4 By Oxidized Phospholipids

189

Fragmented Hyaluronic Acid activates TLR4

189

TLR4 Participates in Inflammation Associated with Ventilator-induced Lung Injury or Cardiac Hypertrophy Produced by Aortic Stenosis

189

TLR4 Participates in Late Inflammatory Responses in which HMGB1 Plays a Contributory Role

190

Heat Shock Proteins (HSP) Induce Pro-inflammatory Cytokine Release through TLR4

190

TLR4 Participates in Ethanol-induced Inflammation

191

Acetaminophen-induced Liver Injury is TLR4-dependent

191

Conclusion

192

References

192

Hydrogen Sulfide: A Metabolic Modulator and a Protective Agent in Animal Models of Reperfusion Injury

195

Introduction

195

The Biological Chemistry of Hydrogen Sulfide

195

H2S as an Inducer of a State Resembling Suspended Animation

196

Protective Effects of H2S in Local or Whole-body Ischemia or Ischemia-reperfusion

198

Conclusion

200

References

200

V Septic Shock

204

‘Myocardial Depression’ or ‘Septic Cardiomyopathy’?

205

Introduction

205

Septic Cardiomyopathy: A Secondary Cardiomyopathy in the Scope of the Systemic Disease, ‘Sepsis’

205

How to Quantify Septic Cardiomyopathy?

208

Septic Cardiomyopathy is of Prognostic Relevance

209

Septic Cardiomyopathy: Triggers and Mechanisms

210

Causal Approaches towards the Treatment of Acute Septic Cardiomyopathy

213

Conclusion

214

References

214

Determinants of Tissue PCO2 in Shock and Sepsis: Relationship to the Microcirculation

217

Introduction

217

Mechanisms of Increase in Venous and Tissue PCO2: The Basics

217

Intramucosal Acidosis in Sepsis

223

References

225

Refining the Tools for Early Goal-directed Therapy in Septic Shock

227

Introduction: Initial Management of Septic Shock

227

Overview of Early Goal-directed Therapy

227

Therapeutic Steps and Goals and Proposed Refinements

230

Other Issues

236

Conclusion

237

References

238

VI Intravenous Fluids

241

Hyperchloremic Metabolic Acidosis: More than Just a Simple Dilutional Effect

242

Introduction

242

Mechanisms Underpinning pH Regulation: A Physico-chemical Approach

242

Effects of Plasma Volume Expansion on pH

244

Clinical Consequences of Hyperchloremic Metabolic Acidosis

245

Conclusion

251

References

251

Old versus New Starches: What do We Know about their Differences?

254

Introduction

254

Hydroxyethyl Starch Pharmacokinetics

254

Volume Effects

255

Renal Effects

257

Coagulation and Bleeding

257

Tissue Storage

259

Pruritus

259

Long-term Survival

260

Conclusion

260

References

261

Impact of Hydroxyethyl Starch on Renal Function

264

Introduction

264

Pharmacokinetic Profile of HES Solutions

264

Pathomechanisms of HES-induced Renal Dysfunction

266

Clinical Evidence of HES-induced Renal Dysfunction

268

Conclusion

271

References

272

Rational Approach to Fluid Therapy in Acute Diabetic Ketoacidosis

275

Introduction

275

Historical Perspective

275

Pathophysiology

276

Aims of Fluid Therapy

277

Optimal Management

278

Conclusion

282

References

282

VII Hemodynamic Support

284

Cardiac Filling Volumes and Pressures in Assessing Preload Responsiveness during Fluid Challenges

285

Introduction

285

Goals and Effects of Fluid Loading: Defining Preload and Fluid Responsiveness

285

Filling Pressures and Volumes of the Heart

286

Physiological Considerations and Clinical Implications

288

Conclusion

291

References

292

Update on Preload Indexes: More Volume than Pressure

295

Introduction

295

Filling Pressures (CVP and PAOP)

295

Continuous Right Ventricular End-diastolic Volume (cRVEDV)

297

Global-end Diastolic Volume and Intrathoracic Blood Volume

299

Conclusion

302

References

302

Monitoring Arterial Blood Pressure and Cardiac Output using Central or Peripheral Arterial Pressure Waveforms

305

Introduction

305

Wave Contour in the Central and Peripheral Arteries

306

Agreement between Central and Peripheral Blood Pressure in Specific Clinical Situations

308

Influence of the Site of Blood Pressure Measurement on Continuous Cardiac Output Estimation

309

Conclusion

314

References

314

Intrathoracic Pressure Regulation for the Treatment of Hypotension

317

Introduction

317

Active Intrathoracic Pressure Regulation Therapy for Apneic Hypotension Patients

317

Intrathoracic Pressure Regulation Therapy and CPR

319

Intrathoracic Pressure Regulation Therapy and Survival Outcomes in Hemorrhagic Shock

320

Intrathoracic Pressure Regulation Therapy and Sepsis

322

Potential Adverse Consequences and Limitations of Intrathoracic Pressure Regulation Therapy

323

Conclusion

323

References

324

Functional Hemodynamic Monitoring: A Personal Perspective

326

Introduction

326

Use of Dynamic Responses to Identify Nascent Cardiovascular States

327

Preload Responsiveness

327

Cardiovascular Sufficiency

328

Future Trends

329

References

330

VIII Airway Management

331

Endotracheal Intubation in the ICU

332

Introduction

332

Care Management Bundle to Increase the Safety of Endotracheal Intubation in the ICU

332

Conclusion

338

References

339

Pediatric Advanced Airway Management Training for Non-anesthesia Residents

341

Introduction

341

Risks associated with Tracheal Intubation and Provider Competence

341

Demand for Pediatric Airway Management Competence in Pediatric Resident Trainees

344

Process of Acquisition and Retention of Pediatric Tracheal Intubation Competence

345

Future Directions

348

Conclusion

348

References

349

Automatic Tube Compensation in the Weaning Process

351

Introduction

351

Automatic Tube Compensation

352

Commercially available Automatic Tube Compensation Systems

352

Potential Clinical Uses of Automatic Tube Compensation

353

Practical Aspects of using Automatic Tube Compensation

356

Conclusion

356

References

356

IX Mechanical Ventilation

358

Extracorporeal Membrane Oxygenation for Cardiac and Pulmonary Indications: Improving Patient Safety

359

Introduction

359

Application of ECMO Today

360

Further Development of ECMO

361

Control and Safety

363

References

366

Patient-ventilator Interaction during Non-invasive Ventilation

368

Introduction

368

NIV in Acute Respiratory Failure

368

Triggering of the Ventilator

369

Pressurization Slope

371

Level of Pressure Support

371

Cycling

372

Masks

373

Conclusion

374

References

374

Variable Mechanical Ventilation: Breaking the Monotony

377

Introduction

377

Patterns of Variability and their Characterization

377

Rationale for the Use of Variable Patterns in Mechanical Ventilation

379

History of Variable Mechanical Ventilation

379

Variable Controlled Mechanical Ventilation

380

Variable Assisted Mechanical Ventilation

381

Why does Respiratory Function Improve during Variable Mechanical Ventilation?

382

Is Variable Mechanical Ventilation Equivalent to Regular Ventilation with Intermittent Sighs?

384

Can Variable Mechanical Ventilation be Injurious?

385

Limitations of Variable Mechanical Ventilation

386

Conclusion

386

References

387

Life-threatening Asthma: Focus on Lung Protection

390

Introduction

390

Epidemiology

390

Definitions

391

Risk Factors

391

Pathophysiology of the Acute Asthma Attack

391

Therapeutic Approach

393

Conclusion

398

References

399

X Respiratory Monitoring

401

Bedside Monitoring of Diaphragm Electrical Activity during Mechanical Ventilation

402

Introduction and Background

402

Bedside Monitoring of EAdi

404

Conclusion

407

References

408

Electrical Impedance Tomography

411

Introduction

411

How Electrical Impedance Tomography Works

411

Clinical Applications

415

Potential Future Applications of Clinical Relevance

419

Conclusion

419

References

420

Regional Ventilation Delay Index: Detection of Tidal Recruitment using Electrical Impedance Tomography

422

Introduction

422

Individual PEEP Setting is Essential

422

Global and Regional Lung Function Parameters

423

Elecrical Impedance Tomography

423

The Concept of the Regional Ventilation Delay Index

424

Implementing Regional Ventilation Delay Index in Clinical Practice

425

Conclusion

428

References

428

Different Approaches to the Analysis of Volumetric Capnography

430

Introduction

430

Capnography: Types and Applications

430

Techniques for Volumetric Capnography Analysis

433

A New Algorithm for Volumetric Capnography Analysis

435

Conclusion

438

References

439

Variation in Extravascular Lung Water in ALI/ARDS Patients using Open Lung Strategy

441

Introduction

441

Measurement of EVLW at the Bedside

441

EVLW in ALI/ARDS Patients

444

Ventilation Strategy in ALI/ARDS and EVLW Variations

444

Conclusion

447

References

447

Clinical Utility of Extravascular Lung Water Measurements

450

Introduction

450

Measurement of EVLW

450

Limitations of the Measurement of EVLW by Transpulmonary Dilution Techniques

452

Clinical Utility of EVLW

455

Conclusion

457

References

457

XI Perioperative Management

460

Rationalizing the Use of Surgical Critical Care: The Role of Cardiopulmonary Exercise Testing

461

Introduction

461

Why Use Cardiopulmonary Exercise Testing as an Assessment Tool?

462

Which Patients should Undergo Cardiopulmonary Exercise Testing?

463

Cardiopulmonary Exercise Testing in Practice

464

Interpretation of Cardiopulmonary Exercise Test Data

466

Risk Stratification and Management using Cardiopulmonary Exercise Testing

468

Case Reports

469

Conclusion

475

References

475

Advanced Minimally Invasive Hemodynamic Monitoring of the High-risk Major Surgery Patient

477

Introduction

477

Definition and Role of Perioperative Optimization

477

Overview of Some Current Advanced Hemodynamic Monitors

479

Decline in Use of Central Venous Catheterization for Major Surgery

486

Conclusion

486

References

486

Post-pneumonectomy Pulmonary Edema

489

Introduction

489

Diagnostic Criteria

489

Prevalence

489

Pathology

490

Etiology

490

Conclusion

495

References

496

The Role of Phenylephrine in Perioperative Medicine

499

Role of the Calcium Sensitizer, Levosimendan, in Perioperative Intensive Care Medicine

514

Inhaled Nitric Oxide Therapy in Adult Cardiac Surgery

527

XII Cardiac Function

536

Use of Natriuretic Peptides in the Emergency Department and the ICU

537

Abnormalities of the ST Segment

545

Functional Mitral Regurgitation in the Critically Ill

557

XIII Cardiopulmonary Resuscitation

566

Feedback to Improve the Quality of CPR

567

The Post-cardiac Arrest Syndrome

577

Use of a Standardized Treatment Protocol for Post-cardiac Resuscitation Care

587

Therapeutic Hypothermia after Cardiac Arrest

601

XIV Renal Function

612

Biomarkers of Acute Kidney Injury in Critical Illness

613

The Role of Biomarkers in Cardiac Surgeryassociated Acute Kidney Injury

622

Neutrophil Gelatinase-associated Lipocalin: An Emerging Biomarker for Angina Renalis

630

XV Hepatosplanchnic Function

637

How does Intra-abdominal Pressure Affect the Daily Management of My Patients?

638

ICG Clearance Monitoring in ICU Patients

655

Acute-on-Chronic Liver Failure in Cirrhosis: Defining and Managing Organ Dysfunction

667

XVI Nutrition

681

The Curse of Overfeeding and the Blight of Underfeeding

682

Enteral Feeding during Circulatory Failure: Myths and Reality

690

Enteral Nutrition with Anti-inflammatory Lipids in ALI/ARDS

702

Glutamine Supplementation in ICU Patients

712

XVII Glucose Control

723

Burn Causes Prolonged Insulin Resistance and Hyperglycemia

724

Glucose Variability in Critically Ill Patients

733

XVIII Adrenal Function

743

Corticosteroid Biology in Critical Illness: Modulatory Mechanisms and Clinical Implications

744

Corticosteroid Treatment of Patients in Septic Shock

756

XIX Coagulation

764

New Anticoagulants: Anti-IIa or Anti-Xa Agents?

765

Emergency Reversal of Anticoagulants

771

XX Neurological Aspects

782

The Role of Imaging in Acute Brain Injury

783

Monitoring and Managing Raised Intracranial Pressure after Traumatic Brain Injury

801

Sepsis-associated Encephalopathy

809

XXI Malignancies

817

Acute Tumor Lysis Syndrome: Diagnosis and Management

818

Life-threatening Neurological Complications in Patients with Malignancies

827

Should We Admit Critically Ill Cancer Patients to the ICU?

844

XXII Drug Dosing

855

Optimizing Drug Dosing in the ICU

856

Relevant CYP450-mediated Drug Interactions in the ICU

867

XXIII Sedation and Analgesia

875

Sedation and Pain Management in the ICU

876

The Role of Dexmedetomidine in Intensive Care

901

Monitoring Delirium in the ICU

910

XXIV ICU Management

927

Intensive Care for the Elderly: Current and Future Concerns

928

ICU Performance: Managing with Balanced Scorecards

937

XXV End-of-Life Issues

951

Managing Conflict at the End-of-Life

960

Strengths and Weaknesses of Substitute Decision Making in the ICU

970

Subject Index

980